OBJECTIVE: To assess the copy number variation of complement C4A and C4B genes in patients with rheumatoid arthritis (RA). METHODS: DNA samples were obtained from 299 patients and controls and analyzed for copy number variation of total complement C4, C4A, and C4B genes. The results were compared by chi-square analysis, and odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated. RESULTS: Chi-square analysis revealed similar distribution patterns of total C4 alleles in RA patients (n = 160), non-RA patients (n = 88), and healthy controls (n = 51). There was no trend toward C4A deficiency as in lupus. Significant differences in C4B distribution were observed in RA patients, in whom an ∼2-fold increase in the frequency of homozygous and/or heterozygous C4B deficiency (0 or 1 allele) (40%) was present relative to non-RA patients or healthy controls (both 21.6%). C4B deficiency was more frequent in seropositive RA patients than in seronegative RA patients (44% versus 31%). The odds of C4B deficiency were 2.99 (95% CI 1.58-5.65) (P = 0.0006) in seropositive RA patients relative to non-RA controls. These findings were confirmed in a larger healthy control cohort, yielding an OR of 1.83 (95% CI 1.21-2.76) (P = 0.0056). The association of the shared epitope with C4B deficiency was significantly greater in seropositive RA patients than in non-seropositive RA controls (96% versus 54.5%) (P < 0.0001), suggesting that C4B deficiency interacts with the shared epitope in the development of seropositive RA. CONCLUSION: Our findings indicate a relationship between C4B copy number variation and RA that approximates that seen between C4A copy number variation and lupus. The concurrence of C4B deficiency and the shared epitope in seropositive RA may have broad implications for our understanding of RA pathogenesis.
OBJECTIVE: To assess the copy number variation of complement C4A and C4B genes in patients with rheumatoid arthritis (RA). METHODS: DNA samples were obtained from 299 patients and controls and analyzed for copy number variation of total complement C4, C4A, and C4B genes. The results were compared by chi-square analysis, and odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated. RESULTS: Chi-square analysis revealed similar distribution patterns of total C4 alleles in RApatients (n = 160), non-RApatients (n = 88), and healthy controls (n = 51). There was no trend toward C4Adeficiency as in lupus. Significant differences in C4B distribution were observed in RApatients, in whom an ∼2-fold increase in the frequency of homozygous and/or heterozygous C4B deficiency (0 or 1 allele) (40%) was present relative to non-RApatients or healthy controls (both 21.6%). C4B deficiency was more frequent in seropositive RApatients than in seronegative RApatients (44% versus 31%). The odds of C4B deficiency were 2.99 (95% CI 1.58-5.65) (P = 0.0006) in seropositive RApatients relative to non-RA controls. These findings were confirmed in a larger healthy control cohort, yielding an OR of 1.83 (95% CI 1.21-2.76) (P = 0.0056). The association of the shared epitope with C4B deficiency was significantly greater in seropositive RApatients than in non-seropositive RA controls (96% versus 54.5%) (P < 0.0001), suggesting that C4B deficiency interacts with the shared epitope in the development of seropositive RA. CONCLUSION: Our findings indicate a relationship between C4B copy number variation and RA that approximates that seen between C4A copy number variation and lupus. The concurrence of C4B deficiency and the shared epitope in seropositive RA may have broad implications for our understanding of RA pathogenesis.
Authors: Yan Yang; Erwin K Chung; Bi Zhou; Carol A Blanchong; C Yung Yu; George Füst; Margit Kovács; Agnes Vatay; Csaba Szalai; István Karádi; Lilian Varga Journal: J Immunol Date: 2003-09-01 Impact factor: 5.422
Authors: Markus M J Nielen; Dirkjan van Schaardenburg; Henk W Reesink; Rob J van de Stadt; Irene E van der Horst-Bruinsma; Margret H M T de Koning; Moud R Habibuw; Jan P Vandenbroucke; Ben A C Dijkmans Journal: Arthritis Rheum Date: 2004-02
Authors: Joyce J B C van Beers; Reinout Raijmakers; Lou-Ella Alexander; Judith Stammen-Vogelzangs; Angelique M C Lokate; Albert J R Heck; Richard B M Schasfoort; Ger J M Pruijn Journal: Arthritis Res Ther Date: 2010-12-23 Impact factor: 5.156
Authors: C A Blanchong; B Zhou; K L Rupert; E K Chung; K N Jones; J F Sotos; W B Zipf; R M Rennebohm; C Yung Yu Journal: J Exp Med Date: 2000-06-19 Impact factor: 14.307
Authors: Jonathan D Jones; B JoNell Hamilton; Gregory J Challener; Artur J de Brum-Fernandes; Pierre Cossette; Patrick Liang; Ariel Masetto; Henri A Ménard; Nathalie Carrier; David L Boyle; Sanna Rosengren; Gilles Boire; William F C Rigby Journal: Arthritis Res Ther Date: 2014-04-25 Impact factor: 5.156
Authors: Katherine E Lintner; Yee Ling Wu; Yan Yang; Charles H Spencer; Georges Hauptmann; Lee A Hebert; John P Atkinson; C Yung Yu Journal: Front Immunol Date: 2016-02-15 Impact factor: 7.561